Inflammatory carcinoma of the breast – Diagnostics – Overview of Information and Clinical Research

Inflammatory breast cancer is a rare and aggressive form of breast cancer that requires immediate medical attention. Understanding when and how to seek proper diagnosis can make a critical difference in starting treatment quickly.

Introduction: Who Should Undergo Diagnostics

Anyone experiencing sudden changes in the appearance or feel of their breast should seek medical evaluation right away. Inflammatory breast cancer, often called IBC, develops rapidly and doesn’t follow the typical pattern of other breast cancers. Instead of forming a noticeable lump, this type of cancer blocks the small vessels that drain fluid from the breast, causing distinctive skin changes and swelling.^[1]

Women who notice their breast becoming red, swollen, or warm to the touch within a matter of weeks or months should contact their healthcare provider immediately. The same applies if one breast suddenly appears larger than the other, or if the skin develops a dimpled appearance similar to an orange peel. Because these symptoms can appear quickly and might be mistaken for a simple infection, it’s important not to delay seeking professional advice.^[2]

People at higher risk for inflammatory breast cancer should be especially vigilant about monitoring their breast health. This includes women who are younger than those typically affected by other breast cancers, as well as women of African ancestry, who tend to develop this form of cancer more frequently and at younger ages. Women with obesity also face an increased risk, since having a body mass index of 30 or higher appears to be an independent risk factor.^[3]

It’s particularly important to understand that inflammatory breast cancer often develops between scheduled mammogram screenings. The disease progresses so rapidly that it can arise after a normal mammogram and become advanced before the next scheduled screening. This means that anyone experiencing symptoms should not wait for their next routine appointment but should seek immediate evaluation.^[6]

⚠️ Important

Inflammatory breast cancer symptoms are often confused with breast infections called mastitis, which are common during pregnancy and breastfeeding. If your doctor prescribes antibiotics and your symptoms don’t improve within a week or two, you should return for further evaluation. Don’t assume that lack of improvement simply means you need more time to heal.

Classic Diagnostic Methods

Diagnosing inflammatory breast cancer can be challenging because it doesn’t behave like other forms of breast cancer. The journey typically begins with a physical examination where your healthcare provider will carefully examine your breast, looking for specific changes in skin color, texture, and temperature. They will ask detailed questions about when you first noticed these changes and how quickly they developed, since the rapid onset of symptoms is a key characteristic of this disease.^[10]

A mammogram, which is an X-ray of the breast, is often one of the first imaging tests performed. However, mammograms can miss inflammatory breast cancer or only show indirect signs like thickened breast skin or unusual calcium deposits. Most women with this condition have dense breast tissue, which makes detecting cancer on a mammogram even more difficult. The cancer cells are often spread throughout the breast rather than forming a single mass, so they may not create the distinct shadows that mammograms typically reveal.^[6]

Because mammograms alone are often insufficient, doctors usually recommend additional imaging tests. A breast ultrasound uses sound waves to create pictures of the breast tissue and can detect changes that might not appear on a mammogram. This test is particularly useful for examining dense breast tissue and can help identify areas that need further investigation.^[7]

An MRI, or magnetic resonance imaging scan, provides detailed pictures of the breast using magnets and radio waves instead of radiation. This test can reveal abnormal masses or other changes in breast tissue that other imaging methods might miss. MRI scans are especially helpful when doctors need a more complete picture of what’s happening inside the breast.^[10]

The definitive way to diagnose inflammatory breast cancer is through a biopsy, which involves removing a small sample of tissue for examination under a microscope. There are different types of biopsies, but for inflammatory breast cancer, doctors often remove tissue using a needle that passes through the skin into the suspected cancer cells. They may also perform a skin biopsy, which removes a sample of skin cells from the breast. These samples are sent to a laboratory where a specialist called a pathologist examines them to determine whether cancer cells are present.^[10]

If cancer cells are found, the pathologist will test them for special proteins called receptors. These receptors help determine how the cancer cells grow and what treatments might work best. For example, some inflammatory breast cancers have receptors for hormones like estrogen, while others have a protein called HER2. Knowing which receptors are present helps doctors plan the most effective treatment approach.^[7]

The diagnostic process also includes determining whether the cancer has spread beyond the breast. Inflammatory breast cancer is particularly aggressive and often spreads early, so doctors need to check other parts of the body. A CT scan, or computed tomography scan, creates detailed cross-sectional images of the body and can reveal whether cancer has reached the soft tissues or bones. A bone scan specifically looks for cancer that may have spread to the bones.^[7]

A PET scan, which stands for positron emission tomography, uses radioactive substances called tracers to create images of organs and tissues. This test can detect areas of the body where cells are more active than normal, which often indicates the presence of cancer. PET scans are particularly useful for finding cancer that has spread to distant parts of the body such as the liver, lungs, or brain.^[10]

An important aspect of diagnosis is distinguishing between primary and secondary inflammatory breast cancer. Primary inflammatory breast cancer develops in a previously normal breast, while secondary inflammatory breast cancer refers to inflammatory changes that appear in a breast that already had invasive cancer or that develop after surgery for non-inflammatory breast cancer. This distinction matters because it affects treatment decisions and prognosis.^[3]

⚠️ Important

Inflammatory breast cancer diagnosis requires meeting specific criteria. According to medical guidelines, all of the following must be present: rapid onset of breast redness, swelling, or warmth (with or without a palpable mass), symptoms lasting no more than six months, redness covering at least one-third of the breast, and laboratory confirmation of invasive cancer cells. This standardized approach helps prevent delays and ensures accurate diagnosis.

Diagnostics for Clinical Trial Qualification

When patients with inflammatory breast cancer consider enrolling in clinical trials, they typically undergo additional tests beyond those used for standard diagnosis. These tests help researchers determine whether a patient meets the specific criteria needed to participate in a particular study. The goal is to ensure that the trial includes patients who are most likely to benefit from the experimental treatment being tested, while also collecting data that can be compared across different participants.^[6]

Clinical trials for inflammatory breast cancer often require comprehensive imaging to establish a baseline of the cancer’s extent before treatment begins. This typically includes a combination of mammography, ultrasound, and MRI scans of the breast. Researchers need detailed information about the size and distribution of the cancer, the thickness of the skin, and whether swollen lymph nodes are present under the arm or near the collarbone. These images serve as comparison points to measure how well the experimental treatment is working.^[10]

Blood tests are commonly required for clinical trial enrollment to assess overall health and organ function. These tests check how well the liver, kidneys, and bone marrow are working, since many cancer treatments can affect these organs. Trial protocols may exclude patients whose organs aren’t functioning well enough to safely handle the experimental treatment. Blood tests also measure markers that indicate how aggressive the cancer might be or how it might respond to specific therapies.^[7]

Tissue samples from the original biopsy undergo additional specialized testing for clinical trials. Researchers examine the cancer cells for specific molecular characteristics that might predict response to the experimental treatment. This can include testing for hormone receptors (like estrogen and progesterone receptors) and for proteins like HER2. Many trials specifically target cancers with certain molecular profiles, so patients must have tissue samples that can be tested for these markers to qualify for enrollment.^[6]

Staging tests determine how far the cancer has spread, which is crucial for clinical trial eligibility. At diagnosis, inflammatory breast cancer is classified as either stage III or stage IV disease. Stage III means the cancer has spread to nearby lymph nodes but not to distant organs, while stage IV indicates that cancer cells have reached other parts of the body. Some clinical trials only accept patients with one stage or the other, so complete staging through CT scans, bone scans, and PET scans is often necessary.^[6]

Performance status assessments measure how well patients can carry out daily activities. Clinical trials use standardized scales to determine whether patients are healthy enough to tolerate experimental treatments. These assessments evaluate factors like whether patients can work, care for themselves, and stay active. Trials may exclude patients who are too weak or ill to safely participate, since the experimental treatments might pose additional risks.^[3]

Heart function tests are frequently required because some cancer treatments can affect the heart. An echocardiogram, which uses sound waves to create moving pictures of the heart, helps doctors evaluate how well the heart is pumping blood. This is especially important for trials involving drugs that target the HER2 protein, as these medications can sometimes weaken heart function. Patients must have adequate heart function to safely receive such treatments.^[7]

Documentation of previous treatments is essential for clinical trial qualification. Researchers need to know exactly what treatments a patient has already received, including the types of chemotherapy drugs, radiation therapy, surgery, and any targeted therapies or hormone treatments. This information helps ensure that patients haven’t already been exposed to treatments that might interfere with the experimental therapy being studied. It also helps researchers understand how the cancer has responded to standard treatments.^[3]

Prognosis and Survival Rate

Prognosis

The outlook for inflammatory breast cancer tends to be more serious than for other types of breast cancer due to several factors. This form of cancer grows and spreads very quickly, often progressing in just weeks or months rather than years. By the time most people receive their diagnosis, the cancer has already spread to nearby lymph nodes or other areas of the body, including the bones, liver, lungs, or brain. This early spread makes the disease more challenging to treat effectively.^[5]

Several characteristics affect how inflammatory breast cancer progresses. The disease has a high risk of coming back soon after initial treatment, a situation called early recurrence. Additionally, many inflammatory breast cancers are hormone receptor negative, meaning they cannot be treated with hormone therapies that block estrogen-fueled cancer growth. The aggressive nature of the disease and its tendency to be diagnosed at advanced stages contribute to a more challenging prognosis compared to other breast cancer types.^[5]

However, it’s important to know that survival outcomes have been improving modestly over time. Throughout the 1990s and into the 2000s, medical advances have led to better treatment options and gradually improving survival rates. Women who receive prompt diagnosis and comprehensive treatment that combines chemotherapy, surgery, and radiation therapy have better outcomes than those who experience delays in diagnosis or treatment.^[3]

Survival rate

According to statistics from the United States, the five-year relative survival rate for inflammatory breast cancer is 41 percent. This means that, on average, people diagnosed with inflammatory breast cancer have a 41 percent chance of surviving at least five years compared to people without this disease. It’s crucial to understand that this is an average figure, and individual outcomes can vary significantly based on many factors.^[5]

These survival statistics reflect the challenges posed by inflammatory breast cancer’s aggressive nature and tendency to spread early. The disease accounts for only 1 to 5 percent of all breast cancer cases diagnosed in the United States, yet it contributes to approximately 7 percent of breast cancer-related deaths. This disproportionate impact on mortality underscores why rapid diagnosis and immediate treatment are so critical.^[3]

Several factors can influence individual survival outcomes beyond these general statistics. The cancer’s molecular characteristics, such as whether it has hormone receptors or HER2 protein, affect which treatments will work best. The extent of spread at diagnosis also matters significantly – cancer confined to the breast and nearby lymph nodes generally has a better outlook than cancer that has reached distant organs. Overall health, age, and how well the cancer responds to initial treatment all play roles in determining individual prognosis.^[5]

#1 Clinical Trials Search in Europe